ArticleJournal of dental sciences2026
Evaluation of poly-ε-caprolactone/graphene oxide three-dimensional porous scaffolds for potential application in alveolar bone repair.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Alveolar bone reconstruction or regeneration demands the interim porous scaffold. It possesses adequate mechanical properties to enable it to withstand injured bones. These scaffolds are used to regulate the cell growth that migrate from surrounding tissue or are implanted within porous scaffold. This study is devoted to the manufacturing of 3D porous scaffolds and application on repair and regeneration of alveolar bone. Materials and methods: Graphene oxide (GO) was mixed with poly-ε-caprolactone (PCL) material to fabricate 3D porous scaffolds by a solvent-casting/particulate-leaching method. The effects of various concentrations of GO (0.05, 0.1, 0.5, 1, and 2 wt.%) in PCL/GO scaffolds were focused on biological and physical properties. The human osteosarcoma cell (MG-63) in vitro was determined the biocompatibility of PCL/GO scaffolds. Results: The PCL/GO scaffolds had the large porosity (greater than 88 %) in this study ( Conclusion: The 3D porous scaffold had an interconnected structure and its pore diameter was from 250 to 400 μm. Graphene oxide changes the surface properties of the 3D porous scaffold from hydrophobic to hydrophilic. The ALP assay indicated that MG-63 cell differentiated better in PCL/GO scaffolds containing 1 wt.% GO than on other scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.